SPRY2 and central nervous system cancer: DYRK1A prevents endocytotic degradation of EGFR through phosphorylation of the EGFR-signaling modulator Sprouty 2 (SPRY2) and DYRK1A inhibition leads to reduced glioma growth [16, 17].